Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients‐A Population‐Based, Matched Case–Control Study
MG patients have a higher prevalence of both solid and hematologic neoplasms compared to non-myasthenic controls, regardless of immunosuppressive treatment. This supports the notion that malignancy is related to MG disease itself rather than external factors.
Authors
- Eitan Auriel (ORCID: https://orcid.org/0000-0001-6712-5156)
- Yitzhak Friedman
- Itay Lotan (ORCID: https://orcid.org/0000-0002-4015-9783)
- Adi Wilf‐Yarkoni (ORCID: https://orcid.org/0000-0002-2584-5793)
- Tasneem Kab
- Mark Andrew Hellmann (ORCID: https://orcid.org/0000-0002-0010-9407)
- Yiska Loewenberg Weisband (ORCID: https://orcid.org/0000-0002-5064-5902)
- Leor Perl
- Bar Yacobi
- Tzippy Shochat
- Keshet Pardo
- Nitai Shimon
- Liya Bieber
- Nadav Loebl
Institutions
- Reichman University (IL)
- Rabin Medical Center (IL)
- Herzliya Medical Center (IL)
- Teva Pharmaceuticals (Israel) (IL)
- Assaf Harofeh Medical Center (IL)
- Geha Mental Health Center (IL)
- Clalit Health Services (IL)
Publication Details
- Journal
- Muscle & Nerve
- Published
- 2026-03-07
- DOI
- https://doi.org/10.1002/mus.70207
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00